Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy

Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9

Objective(s): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized genome editing.Materials and Methods: I...

Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.

Oncolytic viruses are genetically modified viruses that preferentially replicate in host cancer cells, leading to the production of new viruses and, ultimately, cell death. Currently, no oncolytic viruses that are able to kill only tumor cells while leaving normal cells intact are available. Using T-REx (Invitrogen, Carlsbad, CA) gene switch technology and a self-cleaving ribozyme, we have cons...

Potent Oncolytic Herpes Simplex Virus for the Therapy of Advanced Prostate Cancer

Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.

We have examined the spread and antitumor efficacy of an oncolytic herpes simplex virus-1-based vector (G207) in glioblastoma biopsy spheroids in vitro and in vivo after local delivery to corresponding intracranial xenografts. Spheroids from three patients were infected with increasing doses of G207 and transgene expression was quantified. Other infected spheroids were followed for 10 days to a...

TITLE: A Fusogenic Oncolytic Herpes Simplex Virus for Therapy of Advanced Ovarian Cancer PRINCIPAL INVESTIGATOR:

Purpose and Experimental Design: Replication-compe-tent herpes simplex virus [HSV (oncolytic HSV)] holds con-siderable promise for treating malignant solid tumors, al-though the potency of the virus needs improvement if its fullclinical potential is to be realized. Incorporation of mem-brane fusion capability into an oncolytic HSV, either byscreening for a syncytial ...